Literature DB >> 24982035

Measuring the impact of Clostridium difficile Infection with the NAP1 strain on severity and mortality.

Krishna Rao1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24982035      PMCID： PMC4271097          DOI： 10.1093/cid/ciu500

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  13 in total

1.  Lack of association of outcomes with treatment duration and microbiologic susceptibility data in Clostridium difficile infections in a non-NAP1/BI/027 setting.

Authors:  Anilrudh A Venugopal; Kathleen Riederer; Shilpa M Patel; Susanna Szpunar; Houssein Jahamy; Sharon Valenti; Stephen P Shemes; Riad Khatib; Leonard B Johnson
Journal:  Scand J Infect Dis       Date:  2011-11-13

2.  Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe.

Authors:  Michel Warny; Jacques Pepin; Aiqi Fang; George Killgore; Angela Thompson; Jon Brazier; Eric Frost; L Clifford McDonald
Journal:  Lancet       Date:  2005 Sep 24-30       Impact factor: 79.321

3.  An epidemic, toxin gene-variant strain of Clostridium difficile.

Authors:  L Clifford McDonald; George E Killgore; Angela Thompson; Robert C Owens; Sophia V Kazakova; Susan P Sambol; Stuart Johnson; Dale N Gerding
Journal:  N Engl J Med       Date:  2005-12-01       Impact factor: 91.245

4.  Clostridium difficile ribotype does not predict severe infection.

Authors:  Seth T Walk; Dejan Micic; Ruchika Jain; Eugene S Lo; Itishree Trivedi; Eugene W Liu; Luay M Almassalha; Sarah A Ewing; Cathrin Ring; Andrzej T Galecki; Mary A M Rogers; Laraine Washer; Duane W Newton; Preeti N Malani; Vincent B Young; David M Aronoff
Journal:  Clin Infect Dis       Date:  2012-09-12       Impact factor: 9.079

5.  Multihospital outbreak of Clostridium difficile ribotype 027 infection: epidemiology and analysis of control measures.

Authors:  Mamoon A Aldeyab; Michael J Devine; Peter Flanagan; Michael Mannion; Avril Craig; Michael G Scott; Stephan Harbarth; Nathalie Vernaz; Elizabeth Davies; Jon S Brazier; Brian Smyth; James C McElnay; Brendan F Gilmore; Geraldine Conlon; Fidelma A Magee; Feras W Darwish Elhajji; Shaunagh Small; Collette Edwards; Chris Funston; Mary P Kearney
Journal:  Infect Control Hosp Epidemiol       Date:  2011-03       Impact factor: 3.254

6.  Lack of association of tcdC type and binary toxin status with disease severity and outcome in toxigenic Clostridium difficile.

Authors:  Simon D Goldenberg; Gary L French
Journal:  J Infect       Date:  2011-03-21       Impact factor: 6.072

7.  High prevalence of tcdC deletion-carrying Clostridium difficile and lack of association with disease severity.

Authors:  Brandon P Verdoorn; Robert Orenstein; Jon E Rosenblatt; Lynne M Sloan; Cathy D Schleck; William S Harmsen; Lisa M Nyre; Robin Patel
Journal:  Diagn Microbiol Infect Dis       Date:  2009-09-23       Impact factor: 2.803

8.  Complete restriction of fluoroquinolone use to control an outbreak of Clostridium difficile infection at a community hospital.

Authors:  Alexander J Kallen; Angela Thompson; Polly Ristaino; Leigh Chapman; Ainsley Nicholson; Bich-Thuy Sim; Fernanda Lessa; Umid Sharapov; Elaine Fadden; Richard Boehler; Carolyn Gould; Brandi Limbago; David Blythe; L Clifford McDonald
Journal:  Infect Control Hosp Epidemiol       Date:  2009-03       Impact factor: 3.254

9.  Clostridium difficile strain NAP-1 is not associated with severe disease in a nonepidemic setting.

Authors:  Jeffrey Cloud; Laura Noddin; Amanda Pressman; Mary Hu; Ciaran Kelly
Journal:  Clin Gastroenterol Hepatol       Date:  2009-05-22       Impact factor: 11.382

10.  Clinical severity of Clostridium difficile PCR ribotype 027: a case-case study.

Authors:  Oliver W Morgan; Boaventura Rodrigues; Tony Elston; Neville Q Verlander; Derek F J Brown; Jonathan Brazier; Mark Reacher
Journal:  PLoS One       Date:  2008-03-19       Impact factor: 3.240
View more
  3 in total

1.  Clostridium difficile ribotype 027: relationship to age, detectability of toxins A or B in stool with rapid testing, severe infection, and mortality.

Authors:  Krishna Rao; Dejan Micic; Mukil Natarajan; Spencer Winters; Mark J Kiel; Seth T Walk; Kavitha Santhosh; Jill A Mogle; Andrzej T Galecki; William LeBar; Peter D R Higgins; Vincent B Young; David M Aronoff
Journal:  Clin Infect Dis       Date:  2015-03-31       Impact factor: 9.079

2.  The evolving epidemiology of Clostridium difficile infection in Canadian hospitals during a postepidemic period (2009-2015).

Authors:  Kevin C Katz; George R Golding; Kelly Baekyung Choi; Linda Pelude; Kanchana R Amaratunga; Monica Taljaard; Stephanie Alexandre; Jun Chen Collet; Ian Davis; Tim Du; Gerald A Evans; Charles Frenette; Denise Gravel; Susy Hota; Pamela Kibsey; Joanne M Langley; Bonita E Lee; Camille Lemieux; Yves Longtin; Dominik Mertz; Lorraine Maze Dit Mieusement; Jessica Minion; Dorothy L Moore; Michael R Mulvey; Susan Richardson; Michelle Science; Andrew E Simor; Paula Stagg; Kathryn N Suh; Geoffrey Taylor; Alice Wong; Nisha Thampi
Journal:  CMAJ       Date:  2018-06-25       Impact factor: 8.262

Review 3.  The Antimicrobial Stewardship Approach to Combating Clostridium Difficile.

Authors:  Eric Wenzler; Surafel G Mulugeta; Larry H Danziger
Journal:  Antibiotics (Basel)       Date:  2015-06-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.